Business
Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025Recently completed mid-cycle review meeting with FDA with no significant deficiencies identified; late cycle meeting scheduled for June FDA has indicated intent to convene advisory committee meetingAppointed Dr. Michael Binks as Chief Medical Officer, bringing dee
About this update from Capricor Therapeutics, Inc.
[{"type":"image","alt":"Capricor Therapeutics","displaySize":"","headline":null,"caption":"Capricor Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/9425e1c34a8f71096412f48bc76eaba7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YaI1GjtfVRH2kLVsjMQa4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9425e1c34a8f71096412f48bc76eaba7","width":300,"height":107}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Biologics License Application (BLA) for deramiocel in the treatment of Duchenne muscular dystrophy (DMD) remains under priority review by the U.S. FDA, with a target Prescription Drug User Fee Act (PDUFA) date slated for August 31, 2025","length":236,"tagName":"p"}]},{"val":[{"type":"text","content":"Recently completed mid-cycle review meeting with FDA with no significant deficiencies identified; late cycle meeting scheduled for June ","length":135,"tagName":"p"}]},{"val":[{"type":"text","content":"FDA has indicated intent to convene advisory committee meeting","length":62,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointed Dr. Michael Binks as Chief Medical Officer, bringing deep experience in neuromuscular and rare diseases","length":113,"tagName":"p"}]},{"val":[{"type":"text","content":"The National Institute of Allergy and Infectious Diseases (NIAID) plans to initiate phase 1 clinical trial of Capricor’s StealthX™ exosome vaccine in the third quarter of 2025, subject to NIAID’s regulatory approval","length":215,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash balance of approximately $145 million expected to support planned operations into 2027","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"Capricor will host conference call and webcast today at 4:30 p.m. ET","length":68,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":920,"olType":false},{"type":"text","content":"SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided a corporate update.","length":318,"tagName":"p"},{"type":"text","con...